Health · STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancer
Tango Therapeutics and Revolution Medicines report high tumor response in advanced pancreatic cancer trial
Why it matters
This development highlights the growing potential of combining targeted cancer drugs without chemotherapy to improve outcomes in aggressive malignancies.
The brief
A clinical trial combining an experimental drug from Tango Therapeutics and Revolution Medicines' Rasonque achieved tumor responses in 82% of patients with advanced pancreatic cancer, as reported by STAT News.[1][2] Coverage indicated that 88% of those responding patients remained alive without tumor progression at the nine-month mark.[3] This chemotherapy-free regimen strengthens the scientific rationale for utilizing targeted drug combinations in oncology. STAT News also noted that several other pharmaceutical companies, including Incyte, Verastem, and Hengrui, are actively advancing next-generation therapies targeting RAS gene mutations.[4] These ongoing programs build on earlier approvals like Rasonque to address difficult-to-treat tumors. Reporting from STAT News did not yet disclose the long-term survival data beyond the nine-month assessment period.
What we don’t know yet
- A clinical trial combined an experimental drug from Tango Therapeutics with Revolution Medicines' Rasonque. Only statnews.com reports this so far.
- The clinical trial achieved tumor responses in 82% of patients with advanced pancreatic cancer. Only statnews.com reports this so far.
- Eighty-eight percent of the responding patients remained alive without tumor progression at the nine-month mark. Only statnews.com reports this so far.
- Companies including Incyte, Verastem, and Hengrui are actively advancing next-generation therapies targeting RAS gene mutations. Not yet confirmed by an independent source.
Quick answers
- What happened?
- A clinical trial combining an experimental drug from Tango Therapeutics and Revolution Medicines' Rasonque achieved tumor responses in 82% of patients with advanced pancreatic cancer, as reported by STAT News. Coverage indicated that 88% of those responding patients remained alive without tumor progression at the nine-month mark. This chemotherapy-free regimen strengthens the scientific rationale for utilizing targeted drug combinations in oncology. STAT News also noted that several other pharmaceutical companies, including Incyte, Verastem, and Hengrui, are actively advancing next-generation therapies targeting RAS gene mutations. These ongoing programs build on earlier approvals like Rasonque to address difficult-to-treat tumors. Reporting from STAT News did not yet disclose the long-term survival data beyond the nine-month assessment period.
- Why does it matter?
- This development highlights the growing potential of combining targeted cancer drugs without chemotherapy to improve outcomes in aggressive malignancies.
- How was "Tango Therapeutics and Revolution Medicines report high tumor response in advanced pancreatic cancer trial" verified?
- Citelink grounded this brief in 2 sources, including STAT News. Every claim links to its citation in the sources list below.
Grounding — every claim checked against sources
of 4 grounded3A clinical trial combined an experimental drug from Tango Therapeutics with Revolution Medicines' Rasonque.
The clinical trial achieved tumor responses in 82% of patients with advanced pancreatic cancer.
Eighty-eight percent of the responding patients remained alive without tumor progression at the nine-month mark.
Companies including Incyte, Verastem, and Hengrui are actively advancing next-generation therapies targeting RAS gene mutations.
Don't take our word for it
Run any claim in this Brief through Citelink's verification engine yourself.
Sources
How this brief was made
Citelink’s automated pipeline wrote this summary from the 2 sources listed above, then checked each claim against them before publishing. Briefs are not individually reviewed by a person before they go live, so read the original reporting for the full story.
Spotted an error? Request a correction · Corrections policy